The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. United Therapeutics Corp shares valued at $1,920,043 were purchased by ROTHBLATT MARTINE A on Dec 04 ’25. At $480.01 per share, ROTHBLATT MARTINE A acquired 4,000 shares.
Also, ROTHBLATT MARTINE A purchased 4,000 shares, netting a total of over 1,901,088 in proceeds.
Before that, EDGEMOND JAMES had sold 21,000 shares from its account. In a trade valued at $10,079,696, the CFO AND TREASURER traded United Therapeutics Corp shares for $479.99 each. Upon closing the transaction, the insider’s holdings decreased to 21,000 shares, worth approximately $3.94 million.
As published in their initiating research note from Wells Fargo on October 20, 2025, United Therapeutics Corp [UTHR] has been an Underweight and the price target has been revised to $414. Analysts at RBC Capital Mkts started covering the stock with ‘”an Outperform”‘ outlook in a report released in late September. As of June 02, 2025, Cantor Fitzgerald has initiated its “an Overweight” rating for UTHR. Earlier on April 25, 2025, Wells Fargo downgraded its rating. Their new recommendation was “an Equal weight” for UTHR stock which previously was a “an Overweight”.
Analyzing UTHR Stock Performance
On last trading session, United Therapeutics Corp [NASDAQ: UTHR] rose 0.65% to $484.1. The stock’s lowest price that day was $477.56, but it reached a high of $485.36 in the same session. During the last five days, there has been a drop of approximately -0.89%. Over the course of the year, United Therapeutics Corp shares have jumped approximately 30.80%. Shares of the company reached a 52-week high of $492.62 on 11/26/25 and a 52-week low of $266.98 on 04/09/25.
Support And Resistance Levels for United Therapeutics Corp (UTHR)
According to the 24-hour chart, there is a support level at 478.95, which, if violated, would cause prices to drop to 473.81. In the upper region, resistance lies at 487.85. The next price resistance is at 491.61. RSI (Relative Strength Index) is 65.04 on the 14-day chart, showing neutral technical sentiment.
Is United Therapeutics Corp subject to short interest?
Stocks of United Therapeutics Corp saw a sharp steep in short interest on 2025-11-14 dropping by -0.38 million shares to 1.65 million. Data from Yahoo Finance shows that the short interest on 2025-10-15 was 2.03 million shares. A decline of -23.23% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 2.88 of the overall float, the days-to-cover ratio (short ratio) decline to 2.88.
Which companies own the most shares of United Therapeutics Corp (UTHR)?
In terms of United Therapeutics Corp share price expectations, FactSet research, analysts set an average price target of 550 in the next 12 months, up nearly 14.35% from the previous closing price of $480.96. Analysts anticipate United Therapeutics Corp stock to reach 587 by 2025, with the lowest price target being 447. In spite of this, 7 analysts ranked United Therapeutics Corp stock as Buy at the end of 2025. On April 21, 2025, BofA Securities assigned a price target of “a Neutral” to the stock and upgraded coverage with a $314.
